The global coronary stent market faces continued growth, development and competition from a wide range of technology types and competitors. The market is detailed in a new report from MedMarket Diligence.
FOR IMMEDIATE RELEASE
PRLog (Press Release) – Aug 31, 2009 – Since the advent of coronary stents, followed by the emergence of drug eluting stents, the field of stents in the treatment of coronary artery disease has been characterized by aggressive development of new technologies, from minor changes in strut design and drug-coating processes to more radical thinking of the kind that lead from bare metal stents to drug-eluting stents. The coronary stent market is currently in a phase in which the clinical and market success of drug-eluting stents introduced six years ago has stimulated innovation toward emergence of new drug-eluting stent types from many competitors. While the less invasiveness of coronary stents (delivered percutaneously) and outcomes of drug-eluting stents that are nearly comparable to coronary bypass are enabling coronary stents to expand the absolute market of coronary stents by capturing caseload from CABG, the market once dominated by Johnson & Johnson’s Cordis division is now becoming progressively fragmented with new competitors. The market is now facing new challenges with the pending emergence of bioabsorbable stents, drug-eluting balloons and other competitive alternatives to the established stent market.
The global market for coronary stents, examining the products, technologies, companies and worldwide markets for bare metal, drug-eluting and other coronary stents, is the subject of MedMarket Diligence’s report #C245, "Worldwide Coronary Stents 2008-2017" (published May 2009). See http://www.mediligence.com/rpt/rpt-c245.htm.
"The nature of coronary artery disease, as a major source of morbidity and mortality worldwide, and the support (including especially reimbursement) that treatments receive in the healthcare arena, is a major impetus for technology development," says Patrick Driscoll of MedMarket Diligence. According to Driscoll, there are no fewer than 75 active companies developing and marketing coronary stents and competitive technologies, and the market is likely to become even more consolidated unless new, innovative anti-restenosis technologies are introduced that demonstrate profound clinical advantages over existing options.
The market is facing the emergence, in particular, of bioabsorbable stents, which have demonstrated their potential to provide the necessary anti-restenotic benefit following percutaneous intervention (e.g., angioplasty), then "simply" dissolve and be absorbed at six months or later. Such a device has the potential to eliminate longer term biocompatibility and otherwise inflammatory risk associated with permanently implanted stents. Bioabsorbable stents, too, may be bare or, more likely, contain drug coatings.
The MedMarket Diligence report details the worldwide market for the use of alternative stent devices (cardiac stents or heart stents) in the treatment of coronary artery disease. The report assesses the treatment of coronary artery disease by alternative treatment methodologies (percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other medical/surgical treatment options), with estimated current/forecast caseload across treatment types.
The report details currently approved coronary stents, providing data on current and forecast impact on the market. The report also details the current state of product development in bare stents, drug-coated or drug-eluting stents and bioabsorbable stents in coronary applications and details the products under development, the anticipated timeline and impact of their market introduction. The report assesses the current and ten-year forecast global market for coronary stents, with segmentation by U.S., Europe, Asia/Pacific and Rest of World. The report provides competitor market shares by these geographic regions. The leading and key emerging coronary stent manufacturers are profiled with current product offerings, development status and market strengths/advantages.
The report is described at http://www.mediligence.com/rpt/rpt-c245.htm. The report may be ordered for immediate download at http://www.mediligence.com/store/page30.html.